EHA 2026 Highlights New Directions in Post-Transplant EBV / Lymphoproliferative Disease
EHA 2026 highlights show how PTLD care may be evolving through earlier EBV monitoring, preventive rituximab, and targeted cell therapies for patients whose disease returns or resists standard treatment. Off-the-shelf EBV-specific T-cell therapy tabelecleucel has demonstrated meaningful responses in relapsed or refractory EBV-positive PTLD, while CAR T-cell therapy remains an emerging investigational option.